US Patent 9,333,227

On May 10, 2016 the USPTO issued a patent to Syngulon for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.

US Patent 10,188,114

On January 29, 2019, USPTO issued a second patent to Syngulon covering the use of bacteriocin/immunity for the controlled growth of microorganisms.


Other patents: CN ZL 201480057387.2 + EP3035802B1 + BR112016003533-0 + IN389267

These issued patents are part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive base.

With support from the Wallonia Region of Belgium.

Other patent applications covering Syngulon’s technologies have been filed with USPTO or EPO in 2017, 2018, 2020, 2021 and 2022.